Supernus SUPN
NASDAQ SUPN
$28.56 +0.93 (+3.39%)
As of: Nov 10, 2026 · 2:34 PM EST

Supernus (SUPN) Notes Payables (2022 - 2023)

Updated

Supernus Pharmaceuticals (SUPN) reported Short-Term Borrowings of $402.5 million for Q1 2023, up 0.1% from the prior quarter.

Analysis

Supernus (SUPN) Notes Payables (2022 - 2023) Analysis & Trends

At the end of FY2022, Supernus Pharmaceuticals posted Short-Term Borrowings of $401.97 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Supernus 1.62 Bn 196.50 Mn 199.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 402.50 Mn
Dec 31, 2022 401.97 Mn
API Access

Supernus Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=SUPN&period=max&api_key=YOUR_API_KEY